{"id":8765,"date":"2022-05-24T16:46:56","date_gmt":"2022-05-24T14:46:56","guid":{"rendered":"https:\/\/santediabete.org\/?p=8765"},"modified":"2022-05-24T16:57:44","modified_gmt":"2022-05-24T14:57:44","slug":"une-note-technique-de-sante-diabete-et-medecins-sans-frontiere-pour-documenter-le-prix-de-linsuline-et-des-produits-de-sante","status":"publish","type":"post","link":"https:\/\/santediabete.org\/en_en\/2022\/05\/24\/une-note-technique-de-sante-diabete-et-medecins-sans-frontiere-pour-documenter-le-prix-de-linsuline-et-des-produits-de-sante\/","title":{"rendered":"A technical publication by Sant\u00e9 Diab\u00e8te & M\u00e9decins sans fronti\u00e8res to document the price of insulin and health products"},"content":{"rendered":"
\n

On the occasion of the 75rd<\/sup> World Health Assembly (WHA) being held in Geneva, MSF Access campaign and Sant\u00e9 Diab\u00e8te are publishing a technical document entitled \u201cTowards Insulin for All: Operationalizing the WHA74 Resolution on Diabetes\u201d).<\/p>\n<\/blockquote>\n

In May 2021, during the centenary year of the discovery of insulin, WHO member states passed a resolution on \u201cReducing the burden of noncommunicable diseases through strengthening prevention and control of diabetes\u201d at the 74th World Health Assembly. Within the resolution were specific appeals on access to insulin, directed at both member states and the WHO. This technical brief gives a snapshot of the situation in Kenya, South Africa and Mali [countries where Doctors Without Borders\/M\u00e9decins Sans Fronti\u00e8res (MSF) or Sant\u00e9 Diab\u00e8te provide support for people living with diabetes (PLWD)] regarding these appeals within the resolution. These relate to targets for diabetes care, and inclusion of diabetes and PLWD in national policies and guidelines. In addition, using MSF procurement prices along with available public sector price information from South Africa and Mali, the \u201cbundle\u201d price per patient per year is presented. The bundle calculated includes insulin, its injection device and glucose strips for monitoring as part of a typical treatment regimen for both type 1 (T1) and type 2 (T2) diabetes.<\/p>\n

Based on these findings, the brief makes recommendations to countries and the WHO to ensure that treatment options are accessible and affordable for people living with diabetes.<\/p>\n

Download the document.<\/a><\/p>\n

 <\/p>\n

\n
\n
TRANSLATE with <\/span> x<\/span><\/div>\n
\n
English<\/span><\/p>\n
\n
\n
\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Arabic<\/a><\/td>\nHebrew<\/a><\/td>\nPolish<\/a><\/td>\n<\/tr>\n
Bulgarian<\/a><\/td>\nHindi<\/a><\/td>\nPortuguese<\/a><\/td>\n<\/tr>\n
Catalan<\/a><\/td>\nHmong Daw<\/a><\/td>\nRomanian<\/a><\/td>\n<\/tr>\n
Chinese Simplified<\/a><\/td>\nHungarian<\/a><\/td>\nRussian<\/a><\/td>\n<\/tr>\n
Chinese Traditional<\/a><\/td>\nIndonesian<\/a><\/td>\nSlovak<\/a><\/td>\n<\/tr>\n
Czech<\/a><\/td>\nItalian<\/a><\/td>\nSlovenian<\/a><\/td>\n<\/tr>\n
Danish<\/a><\/td>\nJapanese<\/a><\/td>\nSpanish<\/a><\/td>\n<\/tr>\n
Dutch<\/a><\/td>\nKlingon<\/a><\/td>\nSwedish<\/a><\/td>\n<\/tr>\n
English<\/a><\/td>\nKorean<\/a><\/td>\nThai<\/a><\/td>\n<\/tr>\n
Estonian<\/a><\/td>\nLatvian<\/a><\/td>\nTurkish<\/a><\/td>\n<\/tr>\n
Finnish<\/a><\/td>\nLithuanian<\/a><\/td>\nUkrainian<\/a><\/td>\n<\/tr>\n
French<\/a><\/td>\nMalay<\/a><\/td>\nUrdu<\/a><\/td>\n<\/tr>\n
German<\/a><\/td>\nMaltese<\/a><\/td>\nVietnamese<\/a><\/td>\n<\/tr>\n
Greek<\/a><\/td>\nNorwegian<\/a><\/td>\nWelsh<\/a><\/td>\n<\/tr>\n
Haitian Creole<\/a><\/td>\nPersian<\/a><\/td>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

\"\"<\/div>\n<\/div>\n<\/div>\n<\/div>\n